CD20 positive non-Hodgkin's lymphoma

CD20-positive non-Hodgkin's lymphoma comprises a diverse group of hematologic malignancies originating from mature B lymphocytes that express the CD20 surface transmembrane phosphoprotein Primarily affecting the lymphatic and hematopoietic systems, including lymph nodes, spleen, and bone marrow, these neoplasms result from the clonal proliferation of abnormal B cells at various differentiation stages Pathophysiologically, the disease is defined by the immunophenotypic presence of the CD20 antige...

Primarily affecting the lymphatic and hematopoietic systems, including lymph nodes, spleen, and bone marrow, these neoplasms result from the clonal proliferation of abnormal B cells at various differentiation stages Clinical manifestations range from indolent to aggressive presentations, characteristically featuring lymphadenopathy, splenomegaly, systemic B symptoms, and cytopenias secondary to marrow infiltration

Pathophysiologically, the disease is defined by the immunophenotypic presence of the CD20 antigen on the malignant cells, which contributes to abnormal cell-cycle regulation and serves as a primary molecular target for antibody-based therapies

Clinical manifestations range from indolent to aggressive presentations, characteristically featuring lymphadenopathy, splenomegaly, systemic B symptoms, and cytopenias secondary to marrow infiltration

Clinical manifestations range from indolent to aggressive presentations, characteristically featuring lymphadenopathy, splenomegaly, systemic B symptoms, and cytopenias secondary to marrow infiltration